Diabetic Macular Edema Clinical Trial
Official title:
A Phase II, Multicenter, Randomized, Double Masked, Active Comparator-Controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7200220 in Combination With Ranibizumab Administered Intravitreally in Patients With Diabetic Macular Edema
Verified date | June 2024 |
Source | Hoffmann-La Roche |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Study BP43464 is a phase II, multicenter, randomized, double-masked active comparator-controlled study designed to assess the efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of vamikibart in combination with, anti-vascular endothelial growth factor (VEGF) inhibitor, ranibizumab compared with ranibizumab alone in participants with diabetic macular edema. Only one eye will be chosen as the study eye. The duration of the study will be 76 weeks.
Status | Active, not recruiting |
Enrollment | 187 |
Est. completion date | October 1, 2024 |
Est. primary completion date | April 17, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Diagnosis of diabetes mellitus (Type 1 or Type 2) - Macular thickening secondary to diabetic macular edema (DME) involving the center of the macula - Decreased visual acuity attributable primarily to DME - Ability and willingness to provide written informed consent and to comply with the study protocol - Willingness to allow Aqueous Humor collection - For women of childbearing potential: agreement to remain abstinent or use at least one highly effective contraceptive method that results in a failure rate of <1% per year during the treatment period and for at least 12 weeks after the final dose of study treatment Exclusion Criteria: - Hemoglobin A1c (HbA1c) of greater than (>) 12% - Uncontrolled blood pressure, defined as a systolic value greater than (>)180 millimeters of mercury (mmHg) and/or a diastolic value >100 mmHg while a patient is at rest - Currently pregnant or breastfeeding, or intend to become pregnant during the study - Prior treatment with panretinal photocoagulation or macular laser to the study eye - Any intraocular or periocular corticosteroid treatment within the past 16 weeks prior to Day 1 to the study eye - Prior Iluvien or Retisert implants within 3 years prior to Day 1 to the study eye - Prior or concomitant treatment with anti-VEGF therapy within 8 weeks prior to Day 1 to the study eye; Vabysmo^TM within 16 weeks prior to Day 1, prior BeovuĀ® is not permitted - Prior administration of IVT brolucizumab (BeovuĀ®): ever; vamikibart: </=24 weeks prior to Day 1) in either eye - Any proliferative diabetic retinopathy - Active intraocular or periocular infection or active intraocular inflammation in the study eye - Any current or history of ocular disease other than DME that may confound assessment of the macula or affect central vision in the study eye - Any current ocular condition which, in the opinion of the investigator, is currently causing or could be expected to contribute to irreversible vision loss due to a cause other than DME in the study eye - Other protocol-specified inclusion/exclusion criteria may apply |
Country | Name | City | State |
---|---|---|---|
Argentina | Centro Oftalmológico Dr. Charles S.A. | Capital Federal | |
Argentina | Oftalmos | Capital Federal | |
Argentina | Buenos Aires Mácula | Ciudad Autonoma Buenos Aires | |
Argentina | Grupo Laser Vision | Rosario | |
Argentina | Organizacion Medica de Investigacion | San Nicolás | |
Canada | Institut De L'Oeil Des Laurentides | Boisbriand | Quebec |
Canada | The Retina Centre of Ottawa | Ottawa | Ontario |
Canada | Toronto Retina Institute | Toronto | Ontario |
Israel | Rambam Medical Center; Opthalmology | Haifa | |
Israel | Hadassah MC; Ophtalmology | Jerusalem | |
Israel | Rabin MC; Ophtalmology | Petach Tikva | |
Israel | Kaplan Medical Center; Ophtalmology | Rehovot | |
Israel | Tel Aviv Sourasky MC; Ophtalmology | Tel Aviv | |
Korea, Republic of | Pusan National University Hospital | Busan | |
Korea, Republic of | Yeungnam University Medical Center | Daegu | |
Korea, Republic of | Seoul National University Bundang Hospital | Seongnam-si | |
Korea, Republic of | Asan Medical Center | Seoul | |
Korea, Republic of | Kim's Eye Hospital | Seoul | |
Korea, Republic of | Samsung Medical Center | Seoul | |
Poland | Dobry Wzrok Sp Z O O | Gda?sk | |
Poland | Poradnia Okulistyczna i Salon Optyczny w Gliwicach- PRYZMAT | Gliwice | |
Poland | Uniwersyteckie Centrum Kliniczne; UCK im prof. K. Gibinskiego Slaskiego Uniwersytetu Medycznego | Katowice | |
Poland | Centrum Medyczne UNO-MED | Krakow | |
Poland | Centrum Diagnostyki i Mikrochirurgii Oka LENS | Olsztyn | |
Poland | Caminomed | Tarnowskie Góry | |
Puerto Rico | Emanuelli Research and Development Center LLC | Arecibo | |
Spain | Clinica Universitaria de Navarra; Servicio de Oftalmologia | Madrid | |
Spain | Clinica Universitaria de Navarra; Servicio de Oftalmologia | Pamplona | Navarra |
United Kingdom | Gloucestershire Hospitals NHS Foundation Trust | Gloucestershire | |
United Kingdom | Royal Surrey County Hospital | Guildford | |
United Kingdom | Kings College Hospital NHS Foundation Trust | London | |
United Kingdom | Moorfields Eye Hospital NHS Foundation Trust | London | |
United States | Win Retina | Arcadia | California |
United States | Texas Retina Associates | Arlington | Texas |
United States | Verum Research LLC | Eugene | Oregon |
United States | Pinnacle Research Institute | Fort Lauderdale | Florida |
United States | Cumberland Valley Retina Consultants | Hagerstown | Maryland |
United States | Florida Eye Associates | Melbourne | Florida |
United States | Retina Vitreous Associates of Florida | Saint Petersburg | Florida |
United States | Rocky Mountain Retina | Salt Lake City | Utah |
United States | Deep Blue Retina PLLC | Southaven | Mississippi |
United States | Retina Consultants of Texas | The Woodlands | Texas |
United States | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Torrance | California |
United States | Bay Area Retina Associates | Walnut Creek | California |
Lead Sponsor | Collaborator |
---|---|
Hoffmann-La Roche |
United States, Argentina, Canada, Israel, Korea, Republic of, Poland, Puerto Rico, Spain, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Averaged Over Week 44 and Week 48, in Treatment-naïve Participants | Baseline, Week 44 and Week 48 | ||
Secondary | Number of Participants with Systemic and Ocular Adverse Events (AEs) | Up to Week 72 | ||
Secondary | Number of Participants with Abnormal Laboratory Findings, Abnormal Vital Signs Values, or Abnormal Electrocardiogram (ECG) Parameters | Up to Week 72 | ||
Secondary | Number of Participants with Abnormalities in Standard Ophthalmological Assessments | Up to Week 72 | ||
Secondary | Mean Change From Baseline in BCVA Averaged Over Week 44 and Week 48, in Previously Treated Participants | Baseline, Week 44 and Week 48 | ||
Secondary | Mean Change From Baseline in BCVA Averaged Over Week 44 and Week 48, in Overall Enrolled Population | Baseline, Week 44 and Week 48 | ||
Secondary | Mean Change From Baseline in BCVA Averaged Over Week 20 and Week 24, in Treatment-naïve Participants | Baseline, Week 20 and Week 24 | ||
Secondary | Mean Change From Baseline in BCVA Averaged Over Week 20 and Week 24, in Previously Treated Participants | Baseline, Week 20 and Week 24 | ||
Secondary | Mean Change From Baseline in BCVA Averaged Over Week 20 and Week 24, in Overall Enrolled Population | Baseline, Week 20 and Week 24 | ||
Secondary | Mean Change From Baseline in BCVA Averaged Over Week 32 and Week 36, in Treatment-naïve Participants | Baseline, Week 32 and Week 36 | ||
Secondary | Mean Change From Baseline in BCVA Averaged Over Week 32 and Week 36, in Previously Treated Participants | Baseline, Week 32 and Week 36 | ||
Secondary | Mean Change From Baseline in BCVA Averaged Over Week 32 and Week 36, in Overall Enrolled Population | Baseline, Week 32 and Week 36 | ||
Secondary | Mean Change from Baseline in BCVA Over Time | From baseline to end of study (up to Week 72) | ||
Secondary | Percentage of Participants Gaining = 15, = 10, = 5, or = 0 Letters in BCVA Over Time | From baseline to end of study (up to Week 72) | ||
Secondary | Percentage of Participants Avoiding a Loss of = 15, = 10, = 5, or = 0 Letters in BCVA Over Time | From baseline to end of study (up to Week 72) | ||
Secondary | Percentage of of Participants with BCVA = 69 Letters (20/40 Snellen Equivalent) or = 84 Letters (20/20 Snellen Equivalent) Over Time | From baseline to end of study (up to Week 72) | ||
Secondary | Percentage of Participants with BCVA =38 Letters (20/200 Snellen Equivalent) Over Time | From baseline to end of study (up to Week 72) | ||
Secondary | Change from Baseline in Central Subfield Thickness (CST) at Week 48 | Baseline, Week 48 | ||
Secondary | Change from Baseline in CST at Week 36 | Baseline, Week 36 | ||
Secondary | Change from Baseline in CST at Week 24 | Baseline, Week 24 | ||
Secondary | Mean Change from Baseline in CST Over Time | From baseline to end of study (up to Week 72) | ||
Secondary | Percentage of Participants with Absence of Diabetic Macular Edema Over Time | From baseline to end of study (up to Week 72) | ||
Secondary | Number of Participants with Absence of Intraretinal Fluid and/or Subretinal Fluid Over Time | From baseline to end of study (up to Week 72) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03953807 -
A Study to Evaluate the Effectiveness and Safety of OZURDEX® in Patients With Diabetic Macular Edema But Never Treated
|
Phase 4 | |
Completed |
NCT03622580 -
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)
|
Phase 3 | |
Recruiting |
NCT06262737 -
Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol
|
||
Terminated |
NCT04611152 -
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
|
Phase 3 | |
Terminated |
NCT04603937 -
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
|
Phase 3 | |
Active, not recruiting |
NCT04108156 -
This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Participants With Diabetic Macular Edema Compared With Intravitreal Ranibizumab
|
Phase 3 | |
Completed |
NCT02867735 -
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema
|
Phase 1 | |
Withdrawn |
NCT03629210 -
Combination OZURDEX® & EyLea® vs. OZURDEX® Monotherapy in IncompLete-Responders wIth Diabetic Macular Edema
|
Phase 2 | |
Withdrawn |
NCT02842541 -
Safety Study of Intravitreal EBI-031 Given as a Single or Repeat Injection to Subjects With Diabetic Macular Edema
|
Phase 1 | |
Completed |
NCT02221453 -
Cytokine Levels in Patients With Persistent Diabetic Macular Edema Treated With Triamcinolone Acetonide
|
Phase 2 | |
Completed |
NCT02979665 -
Changes to the Retina Following Anti-VEGF Treatments for Diabetic Macular Edema
|
||
Completed |
NCT02556723 -
Intravitreal Injections of Ziv-aflibercept for Macular Diseases
|
N/A | |
Completed |
NCT02000102 -
Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab
|
N/A | |
Completed |
NCT02088229 -
Relating Retinal Structural and Functional Parameters to Visual Acuity in Eyes Undergoing Treatment for Diabetic Macular Edema
|
N/A | |
Terminated |
NCT00779142 -
Utility of Intravitreal Methotrexate in Diabetic Macular Edema Resistant to Conventional Therapies
|
N/A | |
Completed |
NCT01171976 -
Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT00989989 -
Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema
|
Phase 3 | |
Terminated |
NCT00768040 -
Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema
|
Phase 2 | |
Completed |
NCT00683176 -
Effect of Choline Fenofibrate (SLV348) on Macular Edema
|
Phase 2 | |
Completed |
NCT01259609 -
Changes in Ciliary Body Thickness in Patients With Diabetic Macular Edema After Vitrectomy
|
N/A |